Status:
COMPLETED
Amisulpride in Schizophrenic Acute Phase Patients
Lead Sponsor:
Sanofi
Conditions:
Schizophrenia
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
To collect the safety and response of using Amisulpride in acute schizophrenic patients
Eligibility Criteria
Inclusion
- Patient diagnosed as Diagnostic and Statistical Manual of Mental Disorder, 4th edition, as paranoid, disorganized or undifferentiated type of schizophrenia in acute episode
Exclusion
- Patients previously treated with amisulpride
- Patients have comorbidity which may interfere with the treatment or follow-up
- Patients currently taking depot antipsychotics (at least 30 days washout period is needed)
- Patients currently/ or recently (\< 3 months) withdrawn from drug or alcohol abuse
- Pregnant or lactation
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00436371
Start Date
May 1 2005
Last Update
September 5 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Hong Kong, Hong Kong